Application of Clinical Genetics最新文献

筛选

英文中文

Candidate genes of idiopathic pulmonary fibrosis: current evidence and research. 特发性肺纤维化的候选基因：现有证据和研究。

IF 3.1

Application of Clinical Genetics Pub Date : 2016-02-02 eCollection Date: 2016-01-01 DOI: 10.2147/TACG.S61999

Wei Zhou, Yaping Wang

引用次数: 0

The genetics of Charcot–Marie–Tooth disease: current trends and future implications for diagnosis and management 腓骨肌萎缩症的遗传学:目前的趋势和对诊断和管理的未来影响

IF 3.1

Application of Clinical Genetics Pub Date : 2015-10-19 DOI: 10.2147/TACG.S69969

J. Hoyle, M. Isfort, J. Roggenbuck, D. Arnold, C. hoyle

{"title":"The genetics of Charcot–Marie–Tooth disease: current trends and future implications for diagnosis and management","authors":"J. Hoyle, M. Isfort, J. Roggenbuck, D. Arnold, C. hoyle","doi":"10.2147/TACG.S69969","DOIUrl":"https://doi.org/10.2147/TACG.S69969","url":null,"abstract":"Charcot–Marie–Tooth (CMT) disease is the most common hereditary polyneuropathy and is classically associated with an insidious onset of distal predominant motor and sensory loss, muscle wasting, and pes cavus. Other forms of hereditary neuropathy, including sensory predominant or motor predominant forms, are sometimes included in the general classification of CMT, but for the purpose of this review, we will focus primarily on the forms associated with both sensory and motor deficits. CMT has a great deal of genetic heterogeneity, leading to diagnostic considerations that are still rapidly evolving for this disorder. Clinical features, inheritance pattern, gene mutation frequencies, and electrodiagnostic features all are helpful in formulating targeted testing algorithms in practical clinical settings, but these still have shortcomings. Next-generation sequencing (NGS), combined with multigene testing panels, is increasing the sensitivity and efficiency of genetic testing and is quickly overtaking targeted testing strategies. Currently, multigene panel testing and NGS can be considered first-line in many circumstances, although obtaining initial targeted testing for the PMP22 duplication in CMT patients with demyelinating conduction velocities is still a reasonable strategy. As technology improves and cost continues to fall, targeted testing will be completely replaced by multigene NGS panels that can detect the full spectrum of CMT mutations. Nevertheless, clinical acumen is still necessary given the variants of uncertain significance encountered with NGS. Despite the current limitations, the genetic diagnosis of CMT is critical for accurate prognostication, genetic counseling, and in the future, specific targeted therapies. Although whole exome and whole genome sequencing strategies have the power to further elucidate the genetics of CMT, continued technological advances are needed.","PeriodicalId":39131,"journal":{"name":"Application of Clinical Genetics","volume":"8 1","pages":"235 - 243"},"PeriodicalIF":3.1,"publicationDate":"2015-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TACG.S69969","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68481709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 62

首页上一页